Recombinant Anti-EGFR x Anti-IGF1R Bispecific Antibody (scFv-CH3) contains two chains. The anti-EGFR scFv is fused to the Knob-CH3 domain via a hinge region and the same as the anti-IGF1R scFv to the Hole-CH3 domain, or vice versa. The KIH CH3 domains can facilitate to form a heterodimer and this bivalent binding leads to improvement in avidity. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Colorectal cancer; Cervical cancer; Breast cancer; Pancreatic cancer therapy.